

Frequently Asked Questions (FAQs)

Who is Proventys?

Proventys is a healthcare technology company committed to advancing personalized medicine through validated predictive solutions delivered at the point of care.

Where is Proventys located?

Proventys is headquartered in Durham, NC, with offices in the Boston, MA area.

What does Proventys do?

Proventys develops validated predictive tests and other point-of-care tools that help clinicians make complex treatment decisions personalized to the patient across a range of disease conditions. At the core of each predictive test is a validated statistical model that leverages clinical data and biomarkers to quantify a patient's risk of developing a disease condition or adverse event, or predict the probability of response to a given therapy. Risk scores and assessments generated by a predictive test are reviewed by a physician along with relevant evidence-based guidelines to help make appropriate treatment decisions for the patient.

Proventys delivers its predictive solutions through its web-based, proprietary decision support platform called the Proventys PDx System.™

What does Proventys strive to accomplish?

Proventys aims to improve the care of patients through predictive, personalized, and preventive approaches to medicine.

What is the benefit of using Proventys' validated predictive solutions?

Proventys' solutions enable qualified healthcare professionals to tailor treatment decisions to the characteristics of individual patients, thereby reducing the likelihood of adverse events and needless expense, while increasing the overall quality of care across the system.

Are Proventys' solutions regulated by the FDA?

Proventys' lead product candidate is considered a medical device and will be submitted to FDA for premarket review and clearance.

Who needs Proventys' predictive solutions?

Proventys' predictive solutions can provide additional support for healthcare professionals, in outpatient and inpatient settings, who are faced with complex treatment decisions.

The company's lead product candidate is a predictive test to assess an adult cancer patient's risk of developing chemotherapy-induced febrile neutropenia (FN), an adverse event marked by high fever, serious infection and hospitalization. Results of the "FN PDx" are used by an oncologist to help determine if appropriate therapy should be

prescribed as a preventive measure to a given patient, as suggested by published guidelines.

The FN PDx is accessible through the Proventys PDx Oncology™ decision support system. The system is currently an investigational device and limited by Federal law to investigational use only.

What is personalized medicine?

Personalized medicine is based on the concept that health management should strongly focus on the individual characteristics of each patient. Through a personalized approach to medicine, we have the power to anticipate adverse events before they happen and tailor treatments and therapies to the unique presentation of each patient, thereby generating the best possible outcome for each patient.

What is prospective care?

The practice of medicine today and of the past has typically been a reactive approach. A person gets sick, visits the doctor and gets treated. Prospective care represents a shift in the past and current mindset, encouraging a predictive, personalized, preventive, participatory approach to medicine that utilizes diagnostic advances, new biomarkers and genomic discoveries.

Where can I learn more about Proventys and its predictive solutions?

For more information, please visit the Proventys Website at www.proventys.com.